Health system factors influencing management of multidrug-resistant tuberculosis in four European Union countries - learning from country experiences.

BACKGROUND: In the European Union and European Economic Area only 38% of multidrug-resistant tuberculosis patients notified in 2011 completed treatment successfully at 24 months' evaluation. Socio-economic factors and patient factors such as demographic characteristics, behaviour and attitudes are associated with treatment outcomes. Characteristics of healthcare systems also affect health outcomes. This study was conducted to identify and better understand the contribution of health system components to successful treatment of multidrug-resistant tuberculosis. METHODS: We selected four European Union countries to provide for a broad range of geographical locations and levels of treatment success rates of the multidrug-resistant tuberculosis cohort in 2009. We conducted semi-structured interviews following a conceptual framework with representatives from policy and planning authorities, healthcare providers and civil society organisations. Responses were organised according to the six building blocks of the World Health Organization health systems framework. RESULTS: In the four included countries, Austria, Bulgaria, Spain, and the United Kingdom, the following healthcare system factors were perceived as key to achieving good treatment results for patients with multidrug-resistant tuberculosis: timely diagnosis of drug-resistant tuberculosis; financial systems that ensure access to a full course of treatment and support for multidrug-resistant tuberculosis patients; patient-centred approaches with strong intersectoral collaboration that address patients' emotional and social needs; motivated and dedicated healthcare workers with sufficient mandate and means to support patients; and cross-border management of multidrug-resistant tuberculosis to secure continuum of care between countries. CONCLUSION: We suggest that the following actions may improve the success of treatment for multidrug-resistant tuberculosis patients: deployment of rapid molecular diagnostic tests; development of context-specific treatment guidance and criteria for hospital admission and discharge in the European context; strengthening patient-centred approaches; development of collaborative mechanisms to ensure cross-border care, and development of long-term sustainable financing strategies.

Viewpoint: Why and how tuberculosis control should be included in health sector reviews.

Sector-wide approaches (SWAps) are currently implemented in several, predominantly highly donor-dependent low-income countries, particularly in Sub-Saharan Africa. SWAp intends to enhance health sector performance, especially efficiency, effectiveness, coherence and sustainability. SWAps have been criticized for not being able to produce tangible results and the credibility of a SWAp would increase substantially if such results in terms of health services outputs could be demonstrated. We argue that the monitoring of tuberculosis within the SWAp reviews held to assess sector performance deserves a higher profile. Tuberculosis constitutes in the first place and one of the major public health problems in most of the countries, where SWAps have been introduced, but provided that the programme is integral part of the sector policy and financial management, the indicators used for monitoring TB control programmes can also be used as excellent proxies for monitoring overall health sector performance.